178 related articles for article (PubMed ID: 3134349)
21. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.
Kroner PA; Friedman KD; Fahs SA; Scott JP; Montgomery RR
J Biol Chem; 1991 Oct; 266(29):19146-9. PubMed ID: 1918030
[TBL] [Abstract][Full Text] [Related]
22. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1995 Jun; 270(23):13826-33. PubMed ID: 7775440
[TBL] [Abstract][Full Text] [Related]
23. The effect of von Willebrand factor on activation of factor VIII by factor Xa.
Koedam JA; Hamer RJ; Beeser-Visser NH; Bouma BN; Sixma JJ
Eur J Biochem; 1990 Apr; 189(2):229-34. PubMed ID: 2110896
[TBL] [Abstract][Full Text] [Related]
24. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
Tang L; Leong L; Sim D; Ho E; Gu JM; Schneider D; Feldman RI; Monteclaro F; Jiang H; Murphy JE
Haemophilia; 2013 Jul; 19(4):539-45. PubMed ID: 23534820
[TBL] [Abstract][Full Text] [Related]
25. A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells.
Shima M; Yoshioka A; Nakajima M; Nakai H; Fukui H
Br J Haematol; 1992 Aug; 81(4):533-8. PubMed ID: 1390241
[TBL] [Abstract][Full Text] [Related]
26. Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets.
Kao KJ; Pizzo SV; McKee PA
J Clin Invest; 1979 Apr; 63(4):656-64. PubMed ID: 108291
[TBL] [Abstract][Full Text] [Related]
27. Substructure of human von Willebrand factor. Proteolysis by V8 and characterization of two functional domains.
Fretto LJ; Fowler WE; McCaslin DR; Erickson HP; McKee PA
J Biol Chem; 1986 Nov; 261(33):15679-89. PubMed ID: 3536910
[TBL] [Abstract][Full Text] [Related]
28. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease.
Weiss HJ; Pietu G; Rabinowitz R; Girma JP; Rogers J; Meyer D
J Lab Clin Med; 1983 Mar; 101(3):411-25. PubMed ID: 6186757
[TBL] [Abstract][Full Text] [Related]
30. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
[TBL] [Abstract][Full Text] [Related]
31. Immunologic studies of native and modified human factor VIII/von Willebrand factor.
Switzer ME; McKee PA
Blood; 1979 Aug; 54(2):310-21. PubMed ID: 88237
[TBL] [Abstract][Full Text] [Related]
32. Characterization of calcium-dependent binding of endogenous factor VIII/von Willebrand factor to surface activated platelets.
Furby FH; Berndt MC; Castaldi PA; Koutts J
Thromb Res; 1984 Sep; 35(5):501-11. PubMed ID: 6435280
[TBL] [Abstract][Full Text] [Related]
33. Purification and characterization of factor VIII 372-Cys: a hypofunctional cofactor from a patient with moderately severe hemophilia A.
O'Brien DP; Pattinson JK; Tuddenham EG
Blood; 1990 Apr; 75(8):1664-72. PubMed ID: 2109644
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of factor VIII-von Willebrand factor association.
Vlot AJ; Koppelman SJ; Meijers JC; Dama C; van den Berg HM; Bouma BN; Sixma JJ; Willems GM
Blood; 1996 Mar; 87(5):1809-16. PubMed ID: 8634427
[TBL] [Abstract][Full Text] [Related]
35. Effect of carbohydrate modifications of factor VIII/von Willebrand factor on binding to platelets.
Goudemand J; Mazurier C; Samor B; Bouquelet S; Montreuil J; Goudemand M
Thromb Haemost; 1985 Jun; 53(3):390-5. PubMed ID: 2864750
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
37. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage.
Precup JW; Kline BC; Fass DN
Blood; 1991 May; 77(9):1929-36. PubMed ID: 1902121
[TBL] [Abstract][Full Text] [Related]
38. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.
Li X; Gabriel DA
Biochemistry; 1997 Sep; 36(35):10760-7. PubMed ID: 9271507
[TBL] [Abstract][Full Text] [Related]
39. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor.
Vlot AJ; Koppelman SJ; van den Berg MH; Bouma BN; Sixma JJ
Blood; 1995 Jun; 85(11):3150-7. PubMed ID: 7756647
[TBL] [Abstract][Full Text] [Related]
40. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII.
Wise RJ; Dorner AJ; Krane M; Pittman DD; Kaufman RJ
J Biol Chem; 1991 Nov; 266(32):21948-55. PubMed ID: 1939217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
